Letter: Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
Restricted accessLetterFirst published online March, 2026
Letter: Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
ReichK, ThyssenJP, BlauveltA, et al.Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized, double-blind, multicenter phase 3 trial. Lancet. 2022; 400(10348):273–282; doi: 10.1016/s0140-6736(22)01199-0
2.
NakaharaT, IzuharaK, OnozukaD, et al.Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study). Clin Exp Allergy. 2023; 53(2):233–238; doi: 10.1111/cea.14267
3.
SmithB, EngelP, WuJJ. Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(24):2299; doi: 10.1056/NEJMc2304782
4.
BernardoD, BieberT, TorresT. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023; 24(5):753–764; doi: 10.1007/s40257-023-00793-5
5.
HaginoT, UchiyamaA, OndaM, et al.Real-world effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: A 16-Week Study in Japan. Dermatitis. 2025; doi: 10.1089/derm.2025.0004
